Nanotherapeutics for enhancing thermal therapy of cancer

International Journal of Hyperthermia

Volumn 23, Issue 6, 2007, Pages 501-511

  Visaria, Rachana ^a   Bischof, John C ^a,b   Loren, Melissa ^b   Williams, Brent ^b   Ebbini, Emad ^b   Paciotti, Giulio ^c   Griffin, Robert ^d  

^a University of Minnesota   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c CytImmune Sciences Inc   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Gold nanoparticle; Nanotherapeutics; Perfusion defect; Thermal therapy; Tumor necrosis factor

Indexed keywords

ANTINEOPLASTIC AGENT; COLLOIDAL GOLD; CYT 6091; NANOPARTICLE; PEGYLATED COLLOIDAL GOLD TUMOR NECROSIS FACTOR ALPHA; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM CELL; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIMODALITY CANCER THERAPY; NEWBORN; NONHUMAN; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR LOCALIZATION;

ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ENDOTHELIAL CELLS; FEMALE; FIBROSARCOMA; GOLD COLLOID; HUMANS; HYPERTHERMIA, INDUCED; MICE; NANOSTRUCTURES; POLYETHYLENE GLYCOLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35548995337     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730701611241     Document Type: Article

References (44)

1. Song, CW, Park, HJ, Lee, CK and Griffin, R. (2005) Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia, 21:8, pp. 761-767.
2. Huilgol, NG (2006) A phase I study to study arsenic trioxide with radiation and hyperthermia in advanced head and neck cancer. Int J Hyperthermia, 22:5, pp. 391-397.
3. Morita, M., Kuwano, H., Matsuda, H., Mori, M. and Sugimachi, K. (1991) Increased hyperthermic response with prostaglandin E1 in VX2 liver carcinoma in rabbits. J Natl Cancer Inst, 83:19, pp. 1395-1400.
4. Shenoy, MA and Singh, BB (1989) Studies on indomethacin as a potentiator for hyperthermic and radiation responses in a mouse fibrosarcoma. Cancer Lett, 45:3, pp. 227-232.
5. Song, CW, Lin, JC and Lyons, JC (1993) Antitumor effect of interleukin 1 alpha in combination with hyperthermia. Cancer Res, 53:2, pp. 324-328.
6. Watanabe, N., Niitsu, Y., Umeno, H., Sone, H., Neda, H., Yamauchi, N., Maeda, M. and Urushizaki, I. (1988) Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res, 48:3, pp. 650-653.
7. Murata, R., Overgaard, J. and Horsman, MR (2001) Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys, 51:4, pp. 1018-1024.
8. Murata, R. and Horsman, MR (2004) Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia, 20:4, pp. 393-404.
9. Horsman, MR, Murata, R. and Overgaard, J. (2001) Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol, 40:4, pp. 497-503.
10. Thorpe, PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res, 10:2, pp. 415-427.
11. Dong, D., Baumeister, P., Swenson, S., Costa, F., Markland, F., Stiles, C., Patterson, JB, Bates, SE and Lee, AS (2005) Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res, 65:13, pp. 5785-5791.
12. Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N., Maeda, M. and Urushizaki, I. (1988) Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res, 48:8, pp. 2179-2183.
13. Waterston, A. and Bower, M. (2004) TNF and cancer: Good or bad?. Cancer Therapy, 2, pp. 131-148.
14. Alikhani, M., Alikhani, Z., Raptis, M. and Graves, DT (2004) TNF-alpha in vivo stimulates apoptosis in fibroblasts through caspase-8 activation and modulates the expression of pro-apoptotic genes. J Cell Physiol, 201:3, pp. 341-348.
15. Havell, EA, Fiers, W. and North, RJ (1988) The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med, 167:3, pp. 1067-1085.
16. van Horssen, R., Hagen, TL Ten and Eggermont, AM (2006) TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist, 11:4, pp. 397-408.
17. Han, B., Iftekhar, A. and Bischof, JC (2004) Improved cryosurgery by use of thermophysical and inflammatory adjuvants. Technol Cancer Res Treat, 3:2, pp. 103-111.
18. Lin, JC, Park, HJ and Song, CW (1996) Combined treatment of IL-1 alpha and TNF-alpha potentiates the antitumour effect of hyperthermia. Int J Hyperthermia, 12:3, pp. 335-344.
19. Maeda, M., Watanabe, N., Yamauchi, N., Tsuji, Y. and Niitsu, Y. (1991) Successful treatment of a case of hepatocellular carcinoma with tumor necrosis factor and local hyperthermia. Gastroenterol Jpn, 26:6, pp. 774-778.
20. Mocellin, S., Rossi, CR, Pilati, P. and Nitti, D. (2005) Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev, 16:1, pp. 35-53.
21. Eggermont, AM, de Wilt, JH and Hagen, TL ten (2003) Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol, 4:7, pp. 429-437.
22. Paciotti, GF, Myer, L., Weinreich, D., Goia, D., Pavel, N., McLaughlin, RE and Tamarkin, L. (2004) Colloidal gold: A novel nanoparticle vector for tumor directed drug delivery. Drug Deliv, 11:3, pp. 169-183.
23. Visaria, RK, Griffin, RJ, Williams, BW, Ebbini, ES, Paciotti, GF and Song, CW (2006) Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery. Mol Cancer Ther, 5:4, pp. 1014-1020.
24. Chao, BH and Bischof, JC (2004) Pre-treatment inflammation induced by TNF-alpha augments cryosurgical injury on human prostate cancer. Cryobiology, 49:1, pp. 10-27.
25. Goel, R., Swanlund, D., Coad, J., Paciotti, GF and Bischof, JC (2007) TNF-α based Accentuation in Cryoinjury-Dose, Delivery and Response. Molecular Cancer Therapeutics, 6:7, pp. 2039-2047.
26. Griffin, RJ, Okajima, K., Ogawa, A. and Song, CW (1999) Radiosensitization of two murine tumours with mild temperature hyperthermia and carbogen breathing. Int J Radiat Biol, 75:10, pp. 1299-1306.
27. Griffin, RJ, Williams, BW, Wild, R., Cherrington, JM, Park, H. and Song, CW (2002) Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res, 62:6, pp. 1702-1706.
28. Davison, PM, Bensch, K. and Karasek, MA (1980) Isolation and growth of endothelial cells from the microvessels of the newborn human foreskin in cell culture. J Invest Dermatol, 75:4, pp. 316-321.
29. Basilico, R., Blomley, MJ, Cosgrove, DO, Liull, JB, Broillet, A., Bauer, A. and Bonomo, L. (2002) The first phase I study of a novel ultrasound contrast agent (BR14): Assessment of safety and efficacy in liver and kidneys. Acad Radiol, 9, pp. S380-S381.
30. Selby, P., Hobbs, S., Viner, C., Jackson, E., Jones, A., Newell, D., Calvert, AH, McElwain, T., Fearon, K. and Humphreys, J. (1987) Tumour necrosis factor in man: Clinical and biological observations. Br J Cancer, 56:6, pp. 803-808.
31. Feyerabend, T., Steeves, R., Wiedemann, GJ, Richter, E. and Robins, HI (1997) Rationale and clinical status of local hyperthermia, radiation, and chemotherapy in locally advanced malignancies. Anticancer Res, 17:4, pp. 2895-2897.
32. Dewhirst, MW, Vujaskovic, Z., Jones, E. and Thrall, D. (2005) Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia, 21:8, pp. 779-790.
33. Horsman, MR and Siemann, DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res, 66:24, pp. 11520-11539.
34. Thompson, JF and de Wilt, JH (2001) Isolated limb perfusion in the management of patients with recurrent limb melanoma: An important but limited role. Ann Surg Oncol, 8:7, pp. 564-565.
35. van der Veen, AH, Eggermont, AM, Seynhaeve, AL, van, T. and Hagen, TL ten (1998) Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats. Int J Cancer, 77:6, pp. 901-906.
36. Li, CY and Dewhirst, MW (2002) Hyperthermia-regulated immunogene therapy. Int J Hyperthermia, 18:6, pp. 586-596.
37. Senzer, N., Mani, S., Rosemurgy, A., Nemunaitis, J., Cunningham, C., Guha, C., Bayol, N., Gillen, M., Chu, K., Rasmussen, C., Rasmussen, H., Kufe, D., Weichselbaum, R. and Hanna, N. (2004) TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors. J Clin Oncol, 22:4, pp. 592-601.
38. Jang, SH, Wientjes, MG and Au, JL (2003) Drug delivery and transport to solid tumors. Pharm Res, 20:9, pp. 1337-1350.
39. Urano, M., Kahn, J. and Kenton, LA (1990) The effect of cis-diamminedichloroplatinum(II) treatment at elevated temperatures on murine fibrosarcoma, FSa-II. Int J Hyperthermia, 6:3, pp. 563-570.
40. Roemer, RB (1999) Engineering aspects of hyperthermia therapy. Annu Rev Biomed Eng, 1, pp. 347-376.
41. Overgaard, J., Gonzalez, D Gonzalez, Hulshof, MC, Arcangeli, G., Dahl, O., Mella, O. and Bentzen, SM (1996) Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia, 12:1, pp. 3-20.
42. Farma, JM, Puhlmann, M., Soriano, PA, Cox, D., Paciotti, GF, Tamarkin, L. and Alexander, HR (2007) Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor. Int J Cancer, 120:11, pp. 2474-2480.
43. Szlosarek, P., Charles, KA and Balkwill, FR (2006) Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer, 42:6, pp. 745-750.
44. Balkwill, F. (2002) Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev, 13:2, pp. 135-141.